Related references
Note: Only part of the references are listed.The NKG2D axis: an emerging target in cancer immunotherapy
Mariya Lazarova et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2019)
Transforming Growth Factor-β Signaling in Immunity and Cancer
Eduard Batlle et al.
IMMUNITY (2019)
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
Anna M. Paczulla et al.
NATURE (2019)
Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients
Silvia C. Formenti et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Immune evasion by TGF-induced miR-183 repression of MICA/B expression in human lung tumor cells
Thu Le Trinh et al.
ONCOIMMUNOLOGY (2019)
Blockade of TGF-β signaling with novel synthetic antibodies limits immune exclusion and improves chemotherapy response in metastatic ovarian cancer models
Daniel Newsted et al.
ONCOIMMUNOLOGY (2019)
An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression
Rika Fujii et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
A Milieu Molecule for TGF-β Required for Microglia Function in the Nervous System
Yan Qin et al.
CELL (2018)
Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer
Silvia C. Formenti et al.
CLINICAL CANCER RESEARCH (2018)
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
Julius Strauss et al.
CLINICAL CANCER RESEARCH (2018)
Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma
Catherine M. Bollard et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
Rewiring T-cell responses to soluble factors with chimeric antigen receptors
Zenan L. Chang et al.
NATURE CHEMICAL BIOLOGY (2018)
Contextual determinants of TGFβ action in development, immunity and cancer
Charles J. David et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models
Folashade Otegbeye et al.
PLOS ONE (2018)
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
Yan Lan et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF beta enhance the efficacy of cancer immunotherapy
Rajani Ravi et al.
NATURE COMMUNICATIONS (2018)
More than Decoration: Roles for Natural Killer Group 2 Member D Ligand expression by immune Cells
Andrew P. Trembath et al.
FRONTIERS IN IMMUNOLOGY (2018)
NKG2D: A Master Regulator of Immune Cell Responsiveness
Felix M. Wensveen et al.
FRONTIERS IN IMMUNOLOGY (2018)
Cutting an NKG2D Ligand Short: Cellular Processing of the Peculiar Human NKG2D Ligand ULBP4
Tobias Zoeller et al.
FRONTIERS IN IMMUNOLOGY (2018)
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
Rikke B. Holmgaard et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
NK cell receptor NKG2D sets activation threshold for the NCR1 receptor early in NK cell development
Vedrana Jelencic et al.
NATURE IMMUNOLOGY (2018)
Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer
Bin Han et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
Davide Melisi et al.
BRITISH JOURNAL OF CANCER (2018)
TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells
Hung C. Tran et al.
CLINICAL CANCER RESEARCH (2017)
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
Yulong Gao et al.
NATURE IMMUNOLOGY (2017)
Cord blood natural killer cells expressing a dominant negative TGF-β receptor: Implications for adoptive immunotherapy for glioblastoma
Eric S. Yvon et al.
CYTOTHERAPY (2017)
Platelet-Derived Ectosomes Reduce NK Cell Function
Salima Sadallah et al.
JOURNAL OF IMMUNOLOGY (2016)
TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
Sebastien Viel et al.
SCIENCE SIGNALING (2016)
TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
Sebastien Viel et al.
SCIENCE SIGNALING (2016)
Genetics, genomics, and evolutionary biology of NKG2D ligands
Raphael Carapito et al.
IMMUNOLOGICAL REVIEWS (2015)
Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation
Marianna Papaspyridonos et al.
NATURE COMMUNICATIONS (2015)
NKG2D Receptor and Its Ligands in Host Defense
Lewis L. Lanier
CANCER IMMUNOLOGY RESEARCH (2015)
Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study
Richard J. Kovacs et al.
CARDIOVASCULAR TOXICOLOGY (2015)
Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia
A. Baragano Raneros et al.
GENES AND IMMUNITY (2015)
A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC)
Sandrine J. Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells
Sarah S. Donatelli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape
Paula Codo et al.
ONCOTARGET (2014)
Regulation of Ligands for the NKG2D Activating Receptor
David H. Raulet et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
A GPI anchor explains the unique biological features of the common NKG2D-ligand allele MICA*008
Omodele Ashiru et al.
BIOCHEMICAL JOURNAL (2013)
Epithelial-Mesenchymal Transition Induces an Antitumor Immune Response Mediated by NKG2D Receptor
Alejandro Lopez-Soto et al.
JOURNAL OF IMMUNOLOGY (2013)
New prospects on the NKG2D/NKG2DL system for oncology
Evelyn Ullrich et al.
ONCOIMMUNOLOGY (2013)
High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas
Maria Raffaella Zocchi et al.
BLOOD (2012)
IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients
B. Schilling et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Tumor Suppressive MicroRNAs miR-34a/c Control Cancer Cell Expression of ULBP2, a Stress-Induced Ligand of the Natural Killer Cell Receptor NKG2D
Anja Heinemann et al.
CANCER RESEARCH (2012)
MiR-10b Downregulates the Stress-Induced Cell Surface Molecule MICB, a Critical Ligand for Cancer Cell Recognition by Natural Killer Cells
Pinchas Tsukerman et al.
CANCER RESEARCH (2012)
Human microRNA-1245 down-regulates the NKG2D receptor in natural killer cells and impairs NKG2D-mediated functions
J. Luis Espinoza et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
The transcription factor Sox4 is a downstream target of signaling by the cytokine TGF-β and suppresses TH2 differentiation
Makoto Kuwahara et al.
NATURE IMMUNOLOGY (2012)
Up-regulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair
Libing Song et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2012)
TGF-β1 Down-Regulation of NKG2D/DAP10 and 2B4/SAP Expression on Human NK Cells Contributes to HBV Persistence
Cheng Sun et al.
PLOS PATHOGENS (2012)
Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1
Yuk Pheel Park et al.
BLOOD (2011)
Direct Signaling between Platelets and Cancer Cells Induces an Epithelial-Mesenchymal-Like Transition and Promotes Metastasis
Myriam Labelle et al.
CANCER CELL (2011)
Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-β1
Miroslaw J. Szczepanski et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-β1 Cytokine
Moses K. Donkor et al.
IMMUNITY (2011)
Latent TGF-β structure and activation
Minlong Shi et al.
NATURE (2011)
A possible mechanism of impaired NK cytotoxicity in cancer patients: down-regulation of DAP10 by TGF-β1
June-Chul Lee et al.
TUMORI JOURNAL (2011)
Natural Killer Cell Cytotoxicity Is Suppressed by Exposure to the Human NKG2D Ligand MICA*008 That Is Shed by Tumor Cells in Exosomes
Omodele Ashiru et al.
CANCER RESEARCH (2010)
Differential Mechanisms of Shedding of the Glycosylphosphatidylinositol (GPI)-anchored NKG2D Ligands
Lola Fernandez-Messina et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8(+) T cells glioma patients
Courtney A. Crane et al.
NEURO-ONCOLOGY (2010)
Hepatitis C Virus (HCV) Evades NKG2D-Dependent NK Cell Responses through NS5A-Mediated Imbalance of Inflammatory Cytokines
Damien Sene et al.
PLOS PATHOGENS (2010)
Platelet-Derived Transforming Growth Factor-β Down-Regulates NKG2D Thereby Inhibiting Natural Killer Cell Antitumor Reactivity
Hans-Georg Kopp et al.
CANCER RESEARCH (2009)
Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha 2 domain
Mareike Wittenbrink et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Cell-Intrinsic Transforming Growth Factor-β Signaling Mediates Virus-Specific CD8+ T Cell Deletion and Viral Persistence In Vivo
Roberto Tinoco et al.
IMMUNITY (2009)
Opposing Effects of TGF-β and IL-15 Cytokines Control the Number of Short-Lived Effector CD8+ T Cells
Shomyseh Sanjabi et al.
IMMUNITY (2009)
Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs
Fernando Cruz-Guilloty et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-beta 1
Hequan Li et al.
JOURNAL OF IMMUNOLOGY (2009)
GARP (LRRC32) is essential for the surface expression of latent TGF-β on platelets and activated FOXP3+ regulatory T cells
Dat Q. Tran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Tumor-associated MICA is shed by ADAM proteases
Inja Waldhauer et al.
CANCER RESEARCH (2008)
Soluble NKG2D ligands: prevalence, release, and functional impact
Helmut Rainer Salih
Frontiers in Bioscience-Landmark (2008)
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy
Nadia Guerra et al.
IMMUNITY (2008)
Human tumor-derived exosomes down-modulate NKG2D expression
Aled Clayton et al.
JOURNAL OF IMMUNOLOGY (2008)
Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D
Noam Stern-Ginossar et al.
NATURE IMMUNOLOGY (2008)
NK cells and cancer immunosurveillance
I. Waldhauer et al.
ONCOGENE (2008)
Loss of TGFβ signaling destabilize homeostasis and promotes squalemous cell carcinomas in stratified epithelia
Geraldine Guasch et al.
CANCER CELL (2007)
Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis
Cristina Cerboni et al.
BLOOD (2007)
In Vivo Expression Pattern of MICA and MICB and Its Relevance to Auto-Immunity and Cancer
Stephanie Schrambach et al.
PLOS ONE (2007)
Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity
Cristina Cerboni et al.
JOURNAL OF GENERAL VIROLOGY (2007)
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer
Nabeel Bardeesy et al.
GENES & DEVELOPMENT (2006)
TGF-β and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells
Guenter Eisele et al.
BRAIN (2006)
Transforming growth factor-β controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms
Ming O. Li et al.
IMMUNITY (2006)
IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-β in NK cells via the c-Jun N-terminal kinase (JNK) pathway
Hyunkeun Song et al.
CELLULAR IMMUNOLOGY (2006)
Proteolytic release of soluble UL16-binding protein 2 from tumor cells
I Waldhauer et al.
CANCER RESEARCH (2006)
CD4+-CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer
MJ Smyth et al.
JOURNAL OF IMMUNOLOGY (2006)
Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion
YT Bryceson et al.
BLOOD (2006)
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
DA Thomas et al.
CANCER CELL (2005)
CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner
F Ghiringhelli et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Inhibition of NK cell activity through TGF-β1 by down-regulation of NKG2D in a murine model of head and neck cancer
S Dasgupta et al.
JOURNAL OF IMMUNOLOGY (2005)
Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo
K Wiemann et al.
JOURNAL OF IMMUNOLOGY (2005)
The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure
D Garrity et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
TGF-β1 uses distinct mechanisms to inhibit IFN-γ expression in CD4+ T cells at priming and at recall:: Differential involvement of Stat4 and T-bet
JT Lin et al.
JOURNAL OF IMMUNOLOGY (2005)
TGF-β1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells
M Ahmadzadeh et al.
JOURNAL OF IMMUNOLOGY (2005)
Cutting edge:: NKG2D is a costimulatory receptor for human naive CD8+ T cells
K Maasho et al.
JOURNAL OF IMMUNOLOGY (2005)
Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells
JS Palumbo et al.
BLOOD (2005)
Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells
JD Coudert et al.
BLOOD (2005)
Cutting edge:: TGF-β induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7
MC Fantini et al.
JOURNAL OF IMMUNOLOGY (2004)
Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors
P André et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
p21Cip1 and p27Kip1 act in synergy to alter the sensitivity of naive T cells to TGF-β-mediated G1 arrest through modulation of IL-2 responsiveness
LA Wolfraim et al.
JOURNAL OF IMMUNOLOGY (2004)
Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients
JC Lee et al.
JOURNAL OF IMMUNOLOGY (2004)
RNA interference targeting transforming growth factor-β enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo
MA Friese et al.
CANCER RESEARCH (2004)
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3
WJ Chen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors:: Consequences for the NK-mediated killing of dendritic cells
R Castriconi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein
SA Welte et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
V Groh et al.
NATURE (2002)
Cutting edge: Down-regulation of MICA on human tumors by proteolytic shedding
HR Salih et al.
JOURNAL OF IMMUNOLOGY (2002)
Mechanism of transforming growth factor β-induced inhibition of T helper type 1 differentiation
L Gorelik et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity
CM Bollard et al.
BLOOD (2002)
Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining
JE Gumperz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Cutting edge: NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment
AI Roberts et al.
JOURNAL OF IMMUNOLOGY (2001)
Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells
L Gorelik et al.
NATURE MEDICINE (2001)
Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo
A Cerwenka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Strategies for target cell recognition by natural killer cells
A Diefenbach et al.
IMMUNOLOGICAL REVIEWS (2001)
Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family
A Steinle et al.
IMMUNOGENETICS (2001)
Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA
PW Li et al.
NATURE IMMUNOLOGY (2001)
Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells
V Groh et al.
NATURE IMMUNOLOGY (2001)
ULBPs, novel MHC class I-related molecules bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor
D Cosman et al.
IMMUNITY (2001)
Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease
L Gorelik et al.
IMMUNITY (2000)
Share Paper
